Covid in Norway: IPH Stopped Disclosing 'Injection Differentials' in Hospitalisation and Death Outcomes as 'Flurona' Season is Here

Also, the incidence of cancer is up by 4.2% in 2021, with breast cancer rates exceeding even the lockdown-adjusted rates

As indicated in late May, the crapification of official data (whatever it may have been worth earlier) continues apace: from the current report by the Institute for Public Health (IPH), which covers weeks 21 and 22, we learn…not much

There are no more official bits and pieces of data on the efficacy of the injections; all one gets is the standard boiler plate ‘assessment’ that ‘high vaccination uptake contributes to protection of severe Covid-19’ while, at the same time, ‘the combined assessment of ongoing surveillance shows that the sinking trend of the epidemic has bottomed out since early May’. As a result, ‘estimates’, or ‘projections’, as the IPH maintains, ‘are now ambiguous’. They further warn that outbreaks with Omicron-like variants—as observed elsewhere—may happen, and that everyone should keep their guard up (p. 2).

Speaking of guards, well, as it happens, influenza hospitalisations have been significantly higher than those ‘for’ Covid-19: in week 21, there were 75 Covid-related hospitalisations, followed by 80 in week 22—while, for influenza, there were 97 and 132 hospitalisations, respectively (p. 2).

The one interesting bit here is the overall distribution of ‘hospitalisations for various respiratory illnesses’: lower respiratory tract infections: 60%, Covid-19: 20%, influenza: 8%, and upper respiratory tract infections: 11%, with RSV making up >1% (p. 2).

There was a bit of excess mortality in weeks 8, 11, 12, and 14 of 2022, as the reports also holds (p. 2).

Other than that, the report is noticeably shorter (at 34 pp.) compared to earlier iterations of between 60-80 pp.

There are, as of this report—and contrary to the last report from week 20—there are no more data, not even any kind of particulars, really, about the differences between ‘vaccinated’ and ‘unvaccinated’.

The IPH appears to be done with reporting on these matters, and I’ll have something to say about this in a moment, but none of the indicators of the past 18 months since the injections were rolled out are in this report anymore.

To the government’s credit, this isn’t so bad, for they never introduced Covid Passports in Norway (but they were itching to do so), and there was but a very brief period of more extreme gaslighting in December 2021, but it was soon overtaken by the events associated with the Omicron wave.

Back on 31 Dec. 2021, I dared a couple of guesses—and now I’m reproducing the link to this piece, as I think it aged quite well:

Covid in Norway: An End-of-2021 Round-Up, one Observation, and a Prognosis for early 2022

Let’s add some bells and whistles, shall we?

In that above piece, I wrote, among other things, the following:

Hence, my (conservative) estimation is that the ‘fully jabbed-and-boosted’, who are found among 88% of the elderly, will soon return to their pre-eminent position among Covid-related hospitalisations and ICU admission. At that point, the IPH will probably stop mentioning anything about these data because they are simply too embarrassing to debate.

The only thing to correct here would be: replace the notion ‘that the “fully jabbed-and-boosted”…are found among 88% of the elderly’ with the current (5 June 2022) set of data: 67% of the entire population over 18 has taken a booster injection.

Now, with the IPH having stopped mentioning anything about the significantly elevated hospitalisation and death rates among the ‘vaccinated’ relative to the ‘unvaccinated’, we’ve arrived at the point in time where the authorities refuse to talk about this.

Speaking of injections, their numbers haven’t moved much for quite some time, as reported a month ago: with uptake cratering, the IPH had announced on 10 May that there was now ‘an excess of Covid vaccines’ in the country. 7.4m doses were ‘donated to over 25 different countries’ through COVAX. Although the piece doesn’t say anything else, this is virtue-signalling at its worst: 7.4m at about US$ 19.50 per each single injection equals approx. US$ 144,300,000, or NOK 1,382,682,600—close to 1.4 billion of my tax moneys thrown away.

And now for some related ‘news’ that no-one seems to care about over at the IPH

Cancer Diagnoses are Up 4.2% in 2021

Curiously enough, though not entirely unrelated, there was a ‘large increase of cancer in Norway’, as revealed by the latest dedicated report. Published on 8 June, we learn, among other things, that diagnostics in 2021 returned to its pre-Covid levels (p. iv), which is largely due to re-established screening activity (which was shut down in spring 2020).

Breast Cancer is up by 15% in 2021, as this highly emotional piece by state broadcaster NRK indicates. That is still higher than the lockdown-deriving decrease of 10% in cancer diagnoses, as explained by the most recent Cancer in Norway report (p. 2).

Let’s not forget that the uptick in cancer incidence is due to the failed government policy of ‘lockdown’ in spring 2020, something Oslo has acknowledged by lifting all restrictions in spring 2022. (Better late than never, I suppose.)

Interestingly, as the Cancer in Norway report explains, the trends appear to be slightly gendered (p. 20):

• The rate for all cancers combined decreased by 3.8% for men and increased by 2.1% for women.

• The rate of prostate cancer decreased by 12.3%.

• The rate of breast cancer increased by 5.2%.

• The rate of lung cancer for men decreased by 8.5% and increased by 3.4% in women.

• The rate of colon cancer decreased by 4.9% in men, and 2.5% in women. The rate of rectal cancer decreased by 10.6% in men and 9.6% in women.

• The rates of melanoma of the skin increased by 10.3% in men and 8.5% in women.

• The rates of non-melanoma skin cancer, increased by 28.4% in men and 31.6% in women.

• Among more uncommon cancers, the notable increase in the rates for liver (especially in men), and thyroid cancer continues.

As to the role of Covid-19, the authors explain (ibid.; my emphases):

In last year’s report (CiN 2020) we could not see any convincing decrease in the incidence for the vast majority of cancers from 2019 to 2020, but there were some exceptions: The incidence rate of breast cancer decreased by 10%. Most likely because the mammographic screening program was shut down for a few months. The centers opened gradually over the summer/fall, but the number of screening examinations were markedly fewer during 2020. Moreover, a 15% decrease in incidence of cervical cancer was seen, most likely caused by lower participation in cervical screening in 2020. There were also fewer uterine and ovarian cancers diagnosed in 2020. Finally, the incidence rate of lung cancer in women decreased by 6%.

In this year’s report we observe that the decline in incidence for breast, ovarian and lung cancer among women in 2020, is followed by an increase in the rates in 2021. For breast cancer we observe that the increase in rates from 2020 to 2021 is most pronounced for women in screening age (50-69 years). Such an increase is not observed for cervical cancer. However, we assume that the numbers for cervical cancer in 2021 is incomplete and is thus difficult to interpret.

Talk about ‘roadkill’, but since cancer kills you slower, this can easily be cast aside and never be talked about again. Let’s not forget that this increase of 4.2% across the board constitutes ‘a larger increase than we experienced in the past couple of years’ before the pandemic. Yes, some of it is due to decreased screenings in 2020, i.e., policy failures, but the authors of the Cancer in Norway report are equally clear that there was an excess increase exceeding the multi-year experiences.

Time will tell whether or not, and if so, how, this is correlated to the injection program, too.